Immediate and One-Year Outcomes of an Asthma-Tailored Pulmonary Rehabilitation Programme in Overweight and Obese People with Difficult-to-Treat Asthma
Helen Ricketts,Varun Sharma,Femke Steffensen,Elaine Mackay,Gordon MacDonald,Duncan Buchan,Michael Lean,Rekha Chaudhuri,Douglas Cowan
DOI: https://doi.org/10.2147/jaa.s466894
2024-09-26
Journal of Asthma and Allergy
Abstract:Helen Clare Ricketts, 1 Varun Sharma, 1 Femke Steffensen, 2 Elaine Mackay, 3 Gordon Wallace MacDonald, 4 Duncan S Buchan, 5 Michael Lean, 6 Rekha Chaudhuri, 7 Douglas C Cowan 4 1 College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK; 2 Glasgow Clinical Research Facility, Glasgow Royal Infirmary, Glasgow, UK; 3 Pulmonary Rehabilitation Team, Glasgow Royal Infirmary, Glasgow, UK; 4 Respiratory Department, Glasgow Royal Infirmary, Glasgow, UK; 5 Division of Sports and Exercise, University of the West of Scotland, Glasgow, UK; 6 School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK; 7 Respiratory Department, Gartnavel General Hospital, Glasgow, UK Correspondence: Douglas C Cowan, Email Introduction: Management of difficult-to-treat asthma is particularly challenging in people with elevated body mass index (BMI). Our randomised controlled trial of pulmonary rehabilitation (PR) showed improved outcomes at 8 weeks. Here we assess immediate and one-year effects of asthma-tailored PR in participants with difficult-to-treat asthma and BMI ≥ 25 kg/m 2 , and identify response predictors. Methods: A prospective observational study of PR, tailored to asthma, comparing outcomes at baseline (V1), immediately after 8 weeks of PR (V2), and at 1 year (V3). Baseline characteristics were compared in responders/non-responders defined by achievement of minimum clinically important difference (MCID) for asthma control questionnaire (ACQ6) (0.5) at 8 weeks and 1 year. Results: Of 92 participants, 56 attended V2 and 45 attended V3. Mean age was 60 (SD 13) years, 60% were female, and median (IQR) BMI was 33.8 (29.5– 38.7) kg/m 2 . At V1, V2, and V3, respectively, there were significant differences in ACQ6 (mean (95% CI): 2.5 (2.1– 2.9), 2.2 (1.8– 2.5), and 2.3 (1.9– 2.7), p < 0.003), Borg breathlessness score post-6-minute walk test (median (IQR): 2 (0.5– 3), 1 (0– 2), and 1 (0.5– 2), p < 0.035), and annualised exacerbations requiring prednisolone (median (IQR): 3 (2– 5), 0 (0– 4.7), and 1.5 (0– 4.2), p MCID for ACQ6 at V2 and 16 (33%) at V3. Participants with higher ACQ6 scores at baseline (suggesting poorer asthma control) were more likely to achieve MCID. Baseline BMI, within the range studied, was not predictive. Conclusion: Pulmonary rehabilitation induced improvements in asthma-related outcomes including perception of breathlessness, asthma control, and exacerbation frequency at 1 year. Those with poorer baseline asthma control were more likely to benefit. Keywords: asthma, difficult-to-treat asthma, obesity, pulmonary rehabilitation Asthma is a heterogeneous condition associated with variable features of cough, wheeze, shortness of breath, and chest tightness, along with variable inflammation of the airways and airway hyper-reactivity. 1 Difficult-to-treat asthma describes asthma with persistent symptoms and/or frequent asthma attacks despite treatment with high-dose inhaled corticosteroids (ICS) plus a long-acting beta 2 agonist (LABA) or leukotriene receptor antagonist (LRTA); or medium-dose ICS plus a LABA or LRTA and an appropriate additional therapy; or continuous or frequent use of oral steroids; and other factors may contribute, eg poor treatment adherence, psychosocial factors, allergy, dysfunctional breathing, and other co-morbidities such as gastro-oesophageal reflux. 2 Obesity is associated with poorer outcomes in asthma, 3–5 and resistance to steroids, 6 the mainstay of asthma treatment. The links between obesity and asthma are complex, multifaceted, and bidirectional, involving changes in chest wall mechanics, airflow limitation, and hyper-responsiveness, as well as increases in inflammation, both systemically and within the airways. 7 Recently there has been a shift towards personalisation of treatment of airways disease by focusing intervention on treatable traits. 8,9 Type 2 inflammation (T2-high asthma) is the treatable trait in asthma with the widest range of treatment options including the biologic treatments targeting IgE, IL-5, and IL-4/13. Obese asthma is a recognised phenotype but with limited treatment options. It is more often associated with T2-low disease, 10–13 and patients may not be eligible for, or respond to, IgE, IL-5, or IL-4/13 targeted therapies; there is a recognition of an obese non-eosinophilic/non-atopic phenotype with late onset, female preponderance, and high symptom expression, 14,15 in particula -Abstract Truncated-
immunology,allergy,respiratory system